244 related articles for article (PubMed ID: 10462551)
1. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.
Scheeff ED; Briggs JM; Howell SB
Mol Pharmacol; 1999 Sep; 56(3):633-43. PubMed ID: 10462551
[TBL] [Abstract][Full Text] [Related]
2. NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex.
Wu Y; Pradhan P; Havener J; Boysen G; Swenberg JA; Campbell SL; Chaney SG
J Mol Biol; 2004 Aug; 341(5):1251-69. PubMed ID: 15321720
[TBL] [Abstract][Full Text] [Related]
3. Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent.
Baruah H; Wright MW; Bierbach U
Biochemistry; 2005 Apr; 44(16):6059-70. PubMed ID: 15835895
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin adducts on a GGG sequence within a DNA duplex studied by NMR spectroscopy and molecular dynamics simulations.
Téletchéa S; Skauge T; Sletten E; Kozelka J
Chemistry; 2009 Nov; 15(45):12320-37. PubMed ID: 19813235
[TBL] [Abstract][Full Text] [Related]
5. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
6. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG; Campbell SL; Bassett E; Wu Y
Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
Malina J; Natile G; Brabec V
Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
[TBL] [Abstract][Full Text] [Related]
8. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link.
Wu Y; Bhattacharyya D; King CL; Baskerville-Abraham I; Huh SH; Boysen G; Swenberg JA; Temple B; Campbell SL; Chaney SG
Biochemistry; 2007 Jun; 46(22):6477-87. PubMed ID: 17497831
[TBL] [Abstract][Full Text] [Related]
9. Marked dependence on carrier-ligand bulk but not on carrier-ligand chirality of the duplex versus single-strand forms of a DNA oligonucleotide with a series of G-Pt(II)-G intrastrand cross-links modeling cisplatin-DNA adducts.
Beljanski V; Villanueva JM; Doetsch PW; Natile G; Marzilli LG
J Am Chem Soc; 2005 Nov; 127(45):15833-42. PubMed ID: 16277526
[TBL] [Abstract][Full Text] [Related]
10. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
Kasparkova J; Vojtiskova M; Natile G; Brabec V
Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
[TBL] [Abstract][Full Text] [Related]
11. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin.
Gelasco A; Lippard SJ
Biochemistry; 1998 Jun; 37(26):9230-9. PubMed ID: 9649303
[TBL] [Abstract][Full Text] [Related]
12. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.
Sharma S; Gong P; Temple B; Bhattacharyya D; Dokholyan NV; Chaney SG
J Mol Biol; 2007 Nov; 373(5):1123-40. PubMed ID: 17900616
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
16. Novel binding interactions of the DNA fragment d(pGpG) cross-linked by the antitumor active compound tetrakis(mu-carboxylato)dirhodium(II,II).
Chifotides HT; Koshlap KM; Pérez LM; Dunbar KR
J Am Chem Soc; 2003 Sep; 125(35):10714-24. PubMed ID: 12940757
[TBL] [Abstract][Full Text] [Related]
17. Unrestrained 5 ns molecular dynamics simulation of a cisplatin-DNA 1,2-GG adduct provides a rationale for the NMR features and reveals increased conformational flexibility at the platinum binding site.
Elizondo-Riojas MA; Kozelka J
J Mol Biol; 2001 Dec; 314(5):1227-43. PubMed ID: 11743736
[TBL] [Abstract][Full Text] [Related]
18. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
[TBL] [Abstract][Full Text] [Related]
19. Investigation relevant to the conformation of the 17-membered Pt(d(GpG)) macrocyclic ring formed by Pt anticancer drugs with DNA: Pt complexes with a Goldilocks carrier ligand.
Maheshwari V; Marzilli PA; Marzilli LG
Inorg Chem; 2011 Jul; 50(14):6626-36. PubMed ID: 21667929
[TBL] [Abstract][Full Text] [Related]
20. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
